MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck (MSD) and Mayo Clinic have launched a research partnership that blends Mayo's Platform architecture and multimodal clinical‑genomic data with MSD's virtual‑cell technologies. The collaboration gives MSD direct access to de‑identified imaging, lab, molecular and notes data to train and validate AI models for drug discovery. Early efforts will focus on therapies for atopic dermatitis, multiple sclerosis and inflammatory bowel disease. The deal follows MSD's recent FDA approvals for Keytruda extensions and ovarian‑cancer regimens.
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck & Co (MSD) and Mayo Clinic have launched a research partnership that leverages AI, advanced analytics, and multimodal clinical‑genomic data to accelerate drug discovery and precision medicine. The collaboration merges Mayo’s Platform architecture and de‑identified datasets—including imaging, labs, molecular...
Verily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience Datasets
Alphabet’s Verily has introduced a free, self‑serve Standard tier for its Pre precision‑health platform, allowing researchers to access the Exchange catalog and Workbench environment with just a Google account. The rollout adds three high‑impact datasets: a single‑cell AML cohort from...
Gold@MnFe‐Prussian Blue Analog Yolk@Shell Nanoparticles for Light‐Triggered and pH‐Sensitive Drug Release
Researchers have engineered Au@MnFe‑Prussian Blue Analog yolk‑shell nanoparticles that combine a hollow cavity with a functional shell for biomedical use. The synthesis creates a ~75 nm interior, achieving roughly 50% loading efficiency for the chemotherapeutic doxorubicin. Partial etching and redeposition of...
Achieving High‐Efficiency Type I Multimodal Photosensitizers via a Synergistic Rigidity‐Flexibility Strategy for Hypoxia‐Resistant Tumor Therapy
Researchers introduced a donor‑acceptor (D‑A) molecular design that couples a rigid coplanar backbone with flexible side chains, dramatically raising near‑infrared molar extinction and fluorescence brightness. The resulting phenothiazine‑based photosensitizer, EL‑TPO2F, also exhibits strong type‑I reactive oxygen species (ROS) production and...
Swedish CubaseBio Emerges From Stealth with €5.9 Million to Scale Volumetric DNA Microscopy
Swedish startup CubaseBio has emerged from stealth after raising €5.9 million in blended financing – a €2 million European Innovation Council grant plus €3.9 million from Voima Ventures, Nordic Science Investments, Illumina Ventures and other life‑science investors. The capital will accelerate development of...
9 Companies Hiring Now in Pennsylvania
Pennsylvania’s Greater Philadelphia corridor remains a biotech hotbed, housing over 1,200 life‑science firms including AstraZeneca, GSK and Johnson & Johnson. Eli Lilly announced a new injectable weight‑loss manufacturing plant in the Lehigh Valley, projected to create roughly 850 jobs by 2031....
Extending Scientific Rigor From Bench to Boardroom
Researchers who launch biotech startups often abandon evidence‑based decision‑making once they enter the boardroom, falling prey to technology myopia, base‑rate neglect, and confirmation bias. Their lack of formal training in commercialization, financial modeling, and competitive analysis amplifies these pitfalls, leading...
Scientists Develop the World’s Tiniest Wireless Brain Implant
Scientists at Cornell University have created a wireless brain implant so small it can sit on a grain of salt, yet still record and transmit neural activity. The device uses light‑based optics for power and data, eliminating bulky wires and...
On Its 15th Anniversary, Foresite Capital Looks Ahead
Foresite Capital marked its 15th anniversary by projecting a resurgence in biopharma venture capital, anticipating a year‑over‑year rise in financings and IPOs starting in 2026. The firm highlighted a surge to $149 billion in biopharma VC dollars in 2025 and a...
Bone Marrow Cell Atlas Created for Improved Leukemia Research
Researchers at the Princess Máxima Center have produced the first multimodal single‑cell atlas of healthy pediatric bone marrow, profiling nearly 91,000 cells from nine donors aged two to 32. The atlas reveals that children’s marrow differs markedly from adult marrow in...
Cancer Immunotherapy Improved Using Targeted Stress Protein
Researchers at NYU Langone Health identified the integrated stress response protein lipocalin 2 (LCN2) as a key mediator that lets lung and pancreatic tumors evade immune attack. In mouse models, antibodies that block LCN2 restored T‑cell infiltration, slowed tumor growth, and...
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences reported its first commercial revenue of $86,000 from limited market release of the nPulse platform and Vibrance disposables. The company completed over 200 procedures across pilot programs and advanced multiple clinical studies, including FDA IDE clearance for the...
Host Control of Persistent Epstein–Barr Virus Infection
A multinational consortium investigated how host genetics influence persistent Epstein‑Barr virus (EBV) infection. Using large‑scale genome‑wide association studies across diverse cohorts, the team identified several host loci that modulate viral load and serostatus. Functional analyses linked these loci to immune...
Blood Test Holds Promise for Predicting when Alzheimer’s Symptoms Will Start
Researchers have developed a blood test that quantifies an abnormal form of tau protein, acting as a molecular clock to predict not only the likelihood of Alzheimer’s disease but also the timing of symptom onset. The study, published in Nature...
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Transcript
Vertex Pharmaceuticals reported fourth‑quarter 2025 revenue of $3.2 billion, a 10% year‑over‑year increase, and full‑year revenue of $12 billion, up 9%. The company highlighted strong growth in its cystic fibrosis (CF) franchise, with 7% global expansion and double‑digit gains in the...
‘An AlphaFold 4’ – Scientists Marvel at DeepMind Drug Spin-Off’s Exclusive New AI
Isomorphic Labs unveiled IsoDDE, a proprietary AI engine touted as an “AlphaFold 4”‑level breakthrough in drug discovery. The 27‑page technical report claims the model outperforms AlphaFold 3, the open‑source Boltz‑2, and traditional physics‑based methods in predicting binding affinity and antibody‑protein interactions. Researchers...
Pharmacogenomics of Antiepileptic Drug Mood Stabilizer Treatment Response in Bipolar Disorder: A MoStGen Consortium Study
The Mood Stabilizer Genomics (MoStGen) Consortium analyzed 917 bipolar disorder patients to identify genetic predictors of response to antiepileptic mood stabilizers (AMS). Genome‑wide association studies revealed a robust association between lamotrigine response and variants in ROBO2, and a gene‑level signal...
A Transcriptional Program Associated with Neurotransmission in the Living Human Brain
Researchers from the Living Brain Project combined prefrontal cortex biopsies from 130 neurosurgical patients with intracranial recordings of dopamine, serotonin, and other neurotransmitters. Differential‑expression analyses of single‑nucleus and bulk RNA‑seq data revealed reproducible gene‑expression signatures that correlate with fast‑scan cyclic...
Exercise Mimetics as Unexplored Therapeutics for Treating Depression
The paper proposes exercise mimetics—pharmacological agents that imitate endurance training—as a novel class of antidepressants. While regular physical activity cuts depression risk by about 18 percent, adherence challenges limit its real‑world impact. Exercise mimetics activate muscle signaling pathways and alter the...
Ardelyx Inc (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx reported Q4 2025 revenue of $110.3 million, driven primarily by a 92% year‑over‑year surge in IBSRELA sales to $78.2 million. The company raised its full‑year IBSRELA revenue guidance to $270‑$275 million and posted a net loss of roughly $1 million, while cash balances...
Insmed Inc (INSM) Q4 2025 Earnings Call Transcript
Insmed reported a $144.6 million net revenue for Brinsupri’s first full U.S. quarter, surpassing internal launch benchmarks. Management set a minimum $1 billion Brinsupri revenue target for 2026 and projected total company revenue to more than double 2025 levels, driven by continued...
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Transcript
Gilead Sciences reported total product sales of $28.9 billion for 2025, a 1% increase that topped the high end of its guidance. The HIV franchise generated $20.8 billion, up 6% overall and 10% on an underlying basis after removing the Medicare Part D...
![[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/3742a25a994e69efcb711edfa308902b.webp)
[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease
Adaptive deep brain stimulation (aDBS) introduces real‑time modulation of stimulation amplitude by tracking subthalamic beta activity, shifting Parkinson's therapy from fixed to physiomarker‑guided. Clinical trials report superior motor improvement, reduced stimulation‑related side effects, and markedly lower energy consumption compared with...
Researchers Develop RNA-Activated Implant to Stimulate Nerve Regrowth After Spinal Cord Injury
Researchers at RCSI have created a 3‑D biomaterial implant that releases PTEN‑targeting siRNA to injured spinal cord neurons, reactivating growth pathways. The scaffold replicates spinal cord mechanical properties and delivers RNA particles directly to the lesion site, silencing the PTEN...
FDA Chief Warns U.S. Is Losing Ground to China in Early Drug Development, Calls for Faster Trial Approvals
FDA Commissioner Marty Makary warned that the United States is falling behind China in early‑stage drug development, citing slower Phase 1 trial volumes and cumbersome regulatory steps. He identified three primary bottlenecks—hospital contracting, ethical review processes, and the IND application workflow—that...
Chemistry-Powered 'Breathing' Membrane Opens and Closes Tiny Pores on Its Own
Researchers at Osaka University have engineered a chemistry‑driven solid‑state membrane that autonomously opens and closes subnanometer pores by reversing the polarity of an applied voltage. The process relies on electrochemical precipitation to block the pore and dissolution to reopen it,...
SPT Labtech, BellBrook Labs Automate Screening for VPS4B ATPase Inhibitors for Cancer Drug Discovery
SPT Labtech and BellBrook Labs announced a joint effort to automate a high‑throughput, cell‑based assay for VPS4B ATPase inhibitors, pairing BellBrook’s Transcreener® ADP2 fluorescence‑polarization assay with SPT’s dragonfly® liquid‑handling system. The miniaturized platform operates in 384‑ and 1536‑well formats and...
Ultrasound-Jiggled Nanobubbles Can Crack Cancer's Collagen 'Fortress'
Researchers at Case Western Reserve University have shown that ultrasound‑activated nanobubbles can mechanically disrupt the dense collagen matrix surrounding solid tumors, creating a temporary “softening” effect that lasts several days. In a breast‑cancer model, the approach enabled deeper penetration of...
Quantum-Level Effects in Biology: Weak Magnetic Fields and Isotopes Can Alter Cell Protein Structures
University of Waterloo researchers demonstrated that weak magnetic fields and isotopic substitution can alter the structure of cellular proteins, specifically tubulin polymerization, in a quantum‑consistent manner. Published in Science Advances, the study bridges structural biology, biophysics, and quantum biology, revealing...
Pediatric Myopia Drug Is Latest In String Of Unexpected FDA Rejections
The FDA has rejected a pediatric myopia drug, citing a lack of substantial evidence for its efficacy. Pediatric ophthalmologists argue the drug, already used in compounded form, effectively slows myopia progression in children. The decision follows a series of recent,...
FDA Backtracks On Moderna mRNA Flu Vaccine Refusal, Sets Aug. 5 Review Deadline
The U.S. Food and Drug Administration has reversed its earlier decision to decline a review of Moderna's mRNA influenza vaccine candidate. Following a Type A meeting with the company, the agency set an August 5, 2026 deadline for completing its evaluation. The...
An Oral Mucosa‐Inspired Wet‐Adhesion Janus Hydrogel With Asymmetric Bifunctionalities of Antifouling/Antioxidant for Treating Oral Ulcer in Diabetes
Researchers have engineered a wet‑adhesion Janus hydrogel (WAJH) that mimics oral mucosa to treat diabetic oral ulcers. The hydrogel features an antifouling agar/polyacrylamide layer and a tannic‑acid‑rich adhesive layer, delivering adhesion energies of 15 J m⁻² and 316 J m⁻² respectively. Its antioxidant tannic...
Training Course: Achieving Data Quality and Integrity in Maximum Containment Laboratories
The FDA and UTMB are hosting a free, week‑long training course on data quality and integrity for BSL‑4 laboratories from July 28 to August 1, 2025, with in‑person seats in Manhattan, Kansas and a virtual option. The curriculum covers GLP requirements, Animal Rule...
NewCo Boom Shows No Signs of Slowing
The NewCo model, where Asian biotech assets are spun out into Western start‑ups backed by Western capital, surged in 2025 with 13 new companies—more than double the six disclosed in 2024. Early 2026 already sees three additional launches, including Kidswell...
FDA to Review Moderna’s Flu Jab on Agency Pivot
The FDA has reversed its earlier refusal and will now evaluate Moderna’s mRNA‑1010 seasonal flu vaccine using a two‑track approach: a full Biologics License Application review for adults 50‑64 and an accelerated approval pathway for those 65 and older, contingent...
Nova-Institut Reports Global Bio-Based Polymer Market to Rise 11% Annually Until 2030
The nova‑Institut report shows bio‑based polymers reached 4.5 million tonnes in 2025, representing about 1 % of total polymer output. Production is projected to grow at an 11 % compound annual growth rate through 2030, potentially doubling the market share to 2 %. Capacity...
Lilly to Pay CSL $100M to License Monoclonal Antibody Targeting IL-6
Eli Lilly has agreed to pay CSL Ltd. $100 million to license the monoclonal antibody clazakizumab, which targets interleukin‑6. Under the agreement, CSL will keep development rights for the drug’s use in preventing cardiovascular complications in end‑stage kidney disease patients, currently...
From DNA To Decision
Rapid functional testing is turning ambiguous genetic variants into actionable medical decisions. A zebrafish model proved a newborn‑identified SMN1 mutation benign, allowing clinicians to defer costly SMA therapy. This proof‑of‑concept shows whole‑genome sequencing can move from data to diagnosis within...
Pharmaceutical Quality Resources
The FDA’s Center for Drug Evaluation and Research created the Office of Pharmaceutical Quality (OPQ) to standardize drug quality oversight across all manufacturing sites, both domestic and foreign. OPQ’s mandate spans new drugs, biologics, generics, biosimilars, over‑the‑counter products, and certain...
FDA Accepts BMS Protein Degrader for Review; Disc Rare Disease Drug Rejected
The FDA has accepted Bristol Myers Squibb’s protein‑degrading multiple myeloma candidate iberdomide for review, with a decision expected by Aug. 17 after a Phase 3 trial showed higher minimal residual disease‑negative rates. In contrast, the agency rejected Disc Medicine’s accelerated‑approval bid for...
Addressing the 58% Launch Failure Rate: Accelerating Market Access Through Intelligent Decision-Making
Pharma launches are missing the mark 58% of the time, a failure rate driven by poor market insight and fragmented decision‑making. Accelerating market‑access planning from pre‑Phase 2 and integrating real‑world data can give companies a strategic north star. Purpose‑built AI tools...
Does the Motion of DNA Influence Its Activity?
Researchers at the Salk Institute demonstrated that the dynamic three‑dimensional folding of the genome directly influences gene expression and cell identity. By depleting the cohesin‑loader protein NIPBL in human iPSC‑derived neurons and cardiomyocytes, they observed region‑specific unfolding of chromatin loops....
STAT+: The FDA’s Moderna Pirouette Is One More Sign of Chaos at the Agency
The FDA initially issued a refuse‑to‑file letter for Moderna’s mRNA influenza vaccine, then reversed course within a week and agreed to review the product. The agency will now consider two separate pathways: full approval for adults 50‑64 and accelerated approval...
Innovation in Ophthalmology: How Biotechs Are Reshaping the Treatment of Eye Diseases
Vision loss remains a leading disability, prompting biotech firms to shift from symptom‑management to disease‑modifying therapies. Gene‑replacement approaches using AAV vectors dominate the inherited retinal disease pipeline, highlighted by Luxturna’s success and multiple late‑stage candidates such as Beacon’s laru‑zova and...
A New Era For Blindness Treatment Is Within Sight
A wave of clinical trials is testing stem‑cell, gene‑editing and bionic‑eye technologies to treat blindness, especially retinitis pigmentosa and dry age‑related macular degeneration. Early‑stage studies from UC Davis, BlueRock Therapeutics and the University of Michigan report measurable vision gains, such as...
Novartis' Oral BTK Drug Moves the Needle in CINDU
Novartis announced that its oral BTK inhibitor Rhapsido (remibrutinib) achieved significantly higher complete response rates than placebo in the phase 3 RemIND trial for the three most common forms of chronic inducible urticaria (CINDU). The drug, already approved for chronic spontaneous...
STAT+: Biotech Startup Raises $175 Million to Advance Alzheimer’s Antibody Therapy
Korsana Biosciences announced a $175 million financing round led by Fairmount, Venrock, Wellington Management and TCGX to develop its Alzheimer’s antibody candidate KRSA‑028. The startup positions KRSA‑028 as a next‑generation “brain shuttle” designed to clear amyloid plaques more efficiently than existing...
NICE Backs First Disease-Modifying Drug for ARG1 Deficiency
Immedica’s pegzilarginase (Loargys), the first enzyme replacement therapy for arginase‑1 (ARG1) deficiency, has received NICE endorsement for NHS use in the UK. The weekly IV or subcutaneous treatment cuts blood arginine levels by roughly 80% and is recommended for patients...
£20M Fund Backs UK Addiction Treatment Tech
The UK government, via Innovate UK, has launched a £20 million funding programme to accelerate development of medicines, medical devices, wearables, virtual‑reality therapies and AI‑enabled tools for drug and alcohol addiction. Grants of up to £10 million for late‑stage projects and up to...
